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characteristics of the cohort based on the presence or
absence of depression has been previously published.5
Given the lack of correlation between these variables and
depression in bivariate models, these variables were not
included in the multivariable model. In addition, the
number of events (52) limited the inclusion of too many
covariates at the risk of over-fitting the model. We agree
with Brown that perhaps one mediator between depression
and poor outcomes could be that those with depression are
more non-adherent to dietary and fluid restrictions, which
in turn leads to worse outcomes.6 Future larger studies are
warranted to address these important questions.
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To the Editor: We read with great interest the article by
Fukui M and colleagues1 evaluating the relationship between
serum bilirubin and albuminuria in patients with type II
diabetes. In this paper, the authors performed a number of
correlations and a multiple regression analysis and concluded
that the serum bilirubin level is associated with microalbu-
minuria and subclinical atherosclerosis in type II diabetic
patients.
However, these results should be interpreted with caution,
as in most of the correlations, the Pearson’s r value was below
0.2, implying a very poor correlation.2 For example, the
coefficient of determination (r2) for bilirubin pulse wave
velocity and bilirubin ankle brachial index, which are early
preclinical markers of atherosclerosis, are 0.1142¼ 0.013 and
0.1182¼ 0.0139, respectively. That is, the proportion of
variance that the variables have in common is 1.3 and
1.39%, respectively; the remaining 98.7 and 98.61% would
probably be explained by other factors, perhaps by HbA1c
levels or other parameters common and sufficiently proven to
be atherogenic in diabetic patients. The fact that these weak
correlations were statistically significant can be explained by
the large sample size of the study but does not mean that
these values are fair enough to imply any important
correlation between the examined variables. Similarly, the
adjusted R2 as well as the tolerance values in the multiple
regression model should be presented, as there seems to be a
degree of co-linearity (between age and duration of diabetes,
BMI, or systolic blood pressure) that might destabilize the
model and lead to indefinite results (for example, triglycer-
ides but not cholesterol were independent determinants of
log (urinary albumin excretion)).
In our opinion, it is quite venturesome and unwarranted
to discuss the potential preventive and therapeutic applica-
tions of bilirubin or its diagnostic utility as a new risk factor
for diabetic nephropathy and atherosclerosis based on the
current data.
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We would like to thank Drs Kassimatis and Moutzouris1
for their interest in our article,2 and the editor for the
opportunity to clarify the several points raised.
Certainly, the Pearson’s r-value between serum bilirubin
concentration and pulse wave velocity and between serum
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bilirubin concentration and ankle–brachial index were low
(o0.2). Those correlations were weak but significant
probably because of the large sample size of the study, as
Dr Kassimatis et al. pointed out.
The main outcome of this study was the negative
correlation between serum bilirubin concentration and
degree of urinary albumin excretion (r¼0.202,
Po0.0001), which is a useful marker of diabetic nephro-
pathy. The adjusted R-square was also low (R2¼ 0.222,
Po0.0001). However, to our surprise, the strength of
serum bilirubin concentration as an independent determi-
nant of log (urinary albumin excretion) was similar to
those of known factors such as systolic blood pressure,
HbA1c, and duration of diabetes in multiple regression
analysis.
We believe that serum bilirubin concentration could be
a protective marker for diabetic nephropathy and athero-
sclerosis in patients with type 2 diabetes. Large prospective
trials are needed to better assess the effects of bilirubin on
diabetic nephropathy and atherosclerosis in patients with
type 2 diabetes.
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To the Editor: We read with interest the article by Fukui
et al.1 showing that serum bilirubin was positively associated
with estimated glomerular filtration rate (e-GFR), and
negatively associated with albuminuria in 633 Japanese type
2 diabetic adults, thus suggesting a renoprotective effect of
bilirubin.
To further investigate the association between serum
bilirubin and kidney function, we performed a retrospective
analysis on the database of our laboratory to retrieve results
of fasting serum bilirubin, glucose, and creatinine tests that
were performed on consecutive adult outpatients (aged 435
years) referred by general practitioners for routine blood
testing over the last 6 months. Similarly to the Fukui et al.
study,1 patients with bilirubin 41.2 mg/100 ml or creatinine
42.0 mg/100 ml were excluded from the study.
Cumulative results for bilirubin and other variables were
retrieved for 2678 adult outpatients (mean age: 55±18 years;
43% male patients), 210 of whom had type 2 diabetes. Serum
bilirubin concentrations were negatively associated with
e-GFR levels, as estimated by the Modification of Diet in
Renal Disease equation, in both non-diabetic (r¼0.17;
Po0.0001) and diabetic patients (r¼0.14; Po0.05).
Accordingly, compared to participants with normal kidney
function, serum bilirubin concentrations were higher
(Po0.001) in those with e-GFR p60 ml/min per 1.73 m2
in both non-diabetic and diabetic groups, independent of age
and gender.
Our findings are in contrast to the results by Fukui et al.,1
and indicate that increased serum bilirubin concentrations,
even within the reference range, are significantly associated
with decreased kidney function in an unselected outpatient
cohort of Caucasian non-diabetic and diabetic adults.
1. Fukui M, Tanaka M, Shiraishi E et al. Relationship between serum bilirubin
and albuminuria in patients with type 2 diabetes. Kidney Int 2008; 74:
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We would like to thank Targher et al.1 for the interest in
our article2 and the editor for the opportunity to clarify
the several points raised.
We are surprised to see their data, which are in contrast
to our result. We cannot be certain of the reason for this
disparity. The possible explanations for this disparity are
as follows. First, mean age (64±12 vs 55±18 years) and
the proportion of male gender (52 vs 43%), which were
determinants of estimated glomerular filtration rate, were
greater in our study compared to those in their study.
Second, serum bilirubin concentrations were significantly
associated with duration of diabetes, diastolic blood
pressure, and serum triglyceride concentration in our
study. The differences in those factors as well as in
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